Recursion Pharmaceuticals, Inc. | TalkMarkets | Page 1
No data available
No data available

People who follow this stock (5)

Latest Posts

About This Stock More About This Stock
AI-Powered Drug Discovery Stocks Index Up 18% Last Week, Led By BioXcel Therapeutics
Article By: Lorimer Wilson
Monday, February 19, 2024 12:05 AM EST
The AI-powered drug discovery market is projected to grow at a 30% CAGR between now and 2030, with annual sales in excess of $50 billion anticipated. An AI drug discovery revolution is underway. 
In this article: EXAI, SDGR, ABCL, BTAI, RLAY, LTRN, ABSI, RXRX
Read
AI-Focused Drug Discovery Stocks Index Up 26% In December
Article By: Lorimer Wilson
Friday, December 29, 2023 11:49 AM EST
With the promise of lower costs and shorter development timelines, AI-enabled drug discovery holds massive potential to increase the accessibility of drugs and to treat presently incurable conditions.
In this article: EXAI, SDGR, ABCL, BTAI, RLAY, LTRN, ABSI, RXRX
Read
AI-Focused Drug Discovery Stocks Index Up 10.6% Last Week
Article By: Lorimer Wilson
Sunday, December 17, 2023 11:20 PM EST
A new study concludes that the AI method of drug discovery is up to 250 times more efficient than the traditional method.
In this article: EXAI, SDGR, ABCL, BTAI, RLAY, LTRN, ABSI, RXRX
Read
The 10 Stocks Using AI To Develop New Drugs Were Up 4%, On Average, Last Week
Article By: Lorimer Wilson
Monday, December 11, 2023 1:14 AM EST
If, as Morgan Stanley postulates, a $50 billion AI drug discovery revolution is underway, here are 10 publicly-traded micro- and small-cap clinical stage pharma companies that are embracing AI to streamline drug discovery and development.
In this article: EXAI, SDGR, ABCL, RLAY, ABSI, RXRX
Read
November Recap: Top 9 Micro/Small Cap AI Stocks Up +53%, On Average
Article By: Lorimer Wilson
Sunday, December 3, 2023 9:49 PM EST
The top 9 micro- and small-cap AI stocks advanced by 53%, on average, in November.
In this article: AIQ, GSIT, AAOI, LMND, RXRX, BBAI
Read

Latest Tweets for $RXRX

No tweets yet!

PARTNER HEADLINES